Alantra advises Inflexion on the sale of Medik8 to L’Oréal

Jun 2025

Sell-side advisory

London –  Alantra has advised Inflexion, a leading European private equity firm, on the sale of Medik8, a UK-based skincare brand, to L’Oréal, the world’s largest beauty powerhouse. This transaction represents a significant milestone for Medik8, providing access to L’Oréal’s global reach and resources to accelerate growth and innovation. As part of the transaction, Inflexion will retain a minority shareholding in Medik8.

Founded in 2009 by Elliot Isaacs, Medik8 is a premium clinical skincare company, offering high-quality active skincare products which deliver clinical results without compromising on experience. Best known for its iconic Crystal Retinal serum and its trademark CSA philosophy, Medik8 has grown into a trusted name in the global skincare industry, with a loyal customer base and a strong presence across key international markets.

During Inflexion’s four-year investment, Medik8 has achieved significant global growth, tripling both its headcount and sales, expanding across Europe, Australia, and notably strengthening its US presence, with US revenue share increasing sevenfold. With Inflexion’s backing, the brand has enhanced its digital capabilities, driving a six-times increase in direct-to-consumer sales, and opened a 100,000 sq. ft. Innovation Centre in the UK.

L’Oréal, the global leader in beauty, boasts an extensive portfolio of iconic brands and a strong commitment to innovation, sustainability, and diversity. Acquiring Medik8 fits L’Oréal’s strategy to expand its presence in the fast-growing science-driven skincare sector.

Matthew Wiseman, Managing Director at Alantra, said: “This transaction builds on our earlier advisory work with Medik8 and Inflexion, and it’s a real source of pride to see Medik8’s remarkable growth journey. Supporting our clients across different stages of their development is central to how we work. We’re excited to see what Medik8 achieves next with L’Oréal’s global platform.”

This transaction further strengthens Alantra’s Health, Beauty & Wellness track record and represents its 14th VMS/H&B sell-side advisory transaction completed in the past 16 months – a powerful testament to our deep expertise and proven ability to deliver results. Recent landmark transactions include advising on the sales of both Dr.G skincare and Medik8 to L’Oréal, Mibelle to Persan, Windstar Medical to Merz Pharma and Nails inc. to Pacific World Corporation, among others.